DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks.
- Published In:
- Diabetes care, 33(6), 1255-61 (2010)
- Authors:
- Buse, John B(10), Drucker, Daniel J(11), Taylor, Kristin L, Kim, Terri, Walsh, Brandon, Hu, Hao, Wilhelm, Ken, Trautmann, Michael, Shen, Larry Z, Porter, Lisa E
- Database ID:
- RPEP-01594
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-01594APA
Buse, John B; Drucker, Daniel J; Taylor, Kristin L; Kim, Terri; Walsh, Brandon; Hu, Hao; Wilhelm, Ken; Trautmann, Michael; Shen, Larry Z; Porter, Lisa E. (2010). DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks.. Diabetes care, 33(6), 1255-61. https://doi.org/10.2337/dc09-1914
MLA
Buse, John B, et al. "DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks.." Diabetes care, 2010. https://doi.org/10.2337/dc09-1914
RethinkPeptides
RethinkPeptides Research Database. "DURATION-1: exenatide once weekly produces sustained glycemi..." RPEP-01594. Retrieved from https://rethinkpeptides.com/research/buse-2010-duration1-exenatide-once-weekly
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.